Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP6 | P55212 | 4/20 | 0.53 |
| ▸ | NSD2 | O96028 | 2/20 | 0.53 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.53 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.53 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.49 |
| ▸ | SNCA | P37840 | 2/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | NT5E | P21589 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SUMO2 | P61956 | 1/20 | 0.41 |
| ▸ | SUMO1 | P63165 | 1/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13965477 | 0.89 | ALDH1A1 (0.50) | CASP6NSD2DUSP3PTPN5PTPN11 | |
| SCHEMBL4299904 | 0.89 | ALDH1A1 (0.47) | CASP6NSD2DUSP3PTPN5PTPN11 | |
| SCHEMBL14469865 | 0.87 | ALDH1A1 (0.64) | CASP6NSD2DUSP3PTPN5PTPN11 | |
| SCHEMBL14299276 | 0.83 | PRMT1 (0.49) | CASP6NSD2DUSP3PTPN5PTPN11 | |
| SCHEMBL14228499 | 0.83 | CYP1A2 (0.52) | CASP6NSD2DUSP3PTPN5PTPN11 | |
| SCHEMBL7037608 | 0.81 | CASP6 (0.59) | CASP6NSD2DUSP3PTPN5PTPN11 | |
| SCHEMBL15851412 | 0.80 | CASP6 (0.41) | CASP6NSD2DUSP3PTPN5PTPN11 | |
| Ammonia Solution, Strong SCHEMBL28873814 | 0.80 | CASP6 (0.57) | CASP6NSD2DUSP3PTPN5PTPN11 | |
| SCHEMBL29462031 | 0.80 | CASP6 (0.77) | CASP6NSD2DUSP3PTPN5PTPN11 | |
| SCHEMBL465086 | 0.80 | CASP6 (0.77) | CASP6NSD2DUSP3PTPN5PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11219691-B2 | Method of treatment or prophylaxis of infections of the eye | STARPHARMA PTY LIMITED (AU) | 2022-01-11 | — | — | US | disclosed |
| US-20210236539-A1 | METHOD OF PROPHYLAXIS OF ZIKA VIRUS INFECTION | STARPHARMA PTY LTD (AU) | 2021-08-05 | — | — | US | disclosed |
| US-20210030785-A1 | METHOD OF PROPHYLAXIS OF ZIKA VIRUS INFECTION | STARPHARMA PTY LTD (AU) | 2021-02-04 | — | — | US | disclosed |
| US-20190070249-A1 | METHOD OF TREATMENT OR PROPHYLAXIS OF INFECTIONS OF THE EYE | STARPHARMA PTY LTD (AU) | 2019-03-07 | — | — | US | disclosed |
| US-9994444-B2 | Bridged polycyclic compound based compositions for the inhibition and amelioration of disease | ALLACCEM, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| EP-2895161-B1 | METHOD OF TREATMENT OR PROPHYLAXIS OF INFECTIONS OF THE EYE | STARPHARMA PTY LTD (AU) | 2017-05-03 | — | — | EP | disclosed |
| US-9155760-B2 | Method of prophylaxis of bacterial vaginosis | STARPHARMA PTY LIMITED (AU) | 2015-10-13 | — | — | US | disclosed |
| US-20150238557-A1 | METHOD OF TREATMENT OR PROPHYLAXIS OF INFECTIONS OF THE EYE | STARPHARMA PTY LIMITED (AU) | 2015-08-27 | — | — | US | disclosed |
| EP-2633087-B1 | NON-METAL TANNING PROCESS | STAHL INT BV (NL) | 2014-09-17 | — | — | EP | disclosed |
| US-8795389-B2 | Non metal tanning | STAHL INTERNATIONAL B.V. (NL) | 2014-08-05 | — | — | US | disclosed |
| WO-2012055481-A1 | NON METAL TANNING | CLARIANT INTERNATIONAL LTD (CH) | 2012-05-03 | — | — | WO | disclosed |
| US-8153618-B2 | Bridged polycyclic compound based compositions for topical applications for pets | ALLACCEM, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153617-B2 | Bridged polycyclic compound based compositions for coating oral surfaces in humans | ALLACCEM, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-20100016270-A1 | BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR CONTROLLING CHOLESTEROL LEVELS | ALLACCEM, INC. | 2010-01-21 | — | — | US | disclosed |
| US-20100004218-A1 | BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR RENAL THERAPY | ALLACCEM, INC. | 2010-01-07 | — | — | US | disclosed |
| US-20090105262-A1 | Bridged polycyclic compound based compositions for coating oral surfaces in humans | ALLACCEM, INC. | 2009-04-23 | — | — | US | disclosed |
| US-20090074833-A1 | BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR CONTROLLING BONE RESORPTION | ALLACCEM, INC. | 2009-03-19 | — | — | US | disclosed |
| US-20090069435-A1 | Bridged polycyclic compound based compositions for topical applications for pets | ALLACCEM, INC. | 2009-03-12 | — | — | US | disclosed |
| US-20090054528-A1 | Bridged polycyclic compound based compositions for coating oral surfaces in pets | ALLACCEM, INC. | 2009-02-26 | — | — | US | disclosed |
| US-20080275141-A1 | BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR THE INHIBITION AND AMELIORATION OF DISEASE | ALLACCEM, INC. | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11219691-B2 | Method of treatment or prophylaxis of infections of the eye | TLR9, TLR1, TLR3 | CASP6 1602/4885NSD2 4083/4885DUSP3 692/4885 |
| US-20090105262-A1 | Bridged polycyclic compound based compositions for coating oral surfaces in humans | PAICS, KRTCAP2, OSTC | CASP6 3709/4885NSD2 2724/4885DUSP3 3753/4885 |
| US-20090069435-A1 | Bridged polycyclic compound based compositions for topical applications for pets | OTC, SLC16A8, SLC16A7 | CASP6 4744/4885NSD2 3577/4885DUSP3 4316/4885 |
| US-20090054528-A1 | Bridged polycyclic compound based compositions for coating oral surfaces in pets | PAICS, SLC16A8, CAD | CASP6 4350/4885NSD2 2076/4885DUSP3 4059/4885 |
| US-20100016270-A1 | BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR CONTROLLING CHOLESTEROL LEVELS | PCSK9, HMGCR, CETP | CASP6 3678/4885NSD2 4020/4885DUSP3 3488/4885 |
| US-20150238557-A1 | METHOD OF TREATMENT OR PROPHYLAXIS OF INFECTIONS OF THE EYE | TLR9, TLR1, TLR3 | CASP6 1602/4885NSD2 4083/4885DUSP3 692/4885 |
| US-20190070249-A1 | METHOD OF TREATMENT OR PROPHYLAXIS OF INFECTIONS OF THE EYE | TLR9, TLR1, TLR3 | CASP6 1602/4885NSD2 4083/4885DUSP3 692/4885 |
| US-20100004218-A1 | BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR RENAL THERAPY | PKD1, PKD2, PAICS | CASP6 3622/4885NSD2 3227/4885DUSP3 4086/4885 |
| US-20090074833-A1 | BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR CONTROLLING BONE RESORPTION | BMP2, BMP1, BMP6 | CASP6 752/4885NSD2 3882/4885DUSP3 2582/4885 |
| US-20080275141-A1 | BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR THE INHIBITION AND AMELIORATION OF DISEASE | PKD1, VHL, PKD2 | CASP6 3236/4885NSD2 3883/4885DUSP3 3860/4885 |
| US-20210030785-A1 | METHOD OF PROPHYLAXIS OF ZIKA VIRUS INFECTION | NAPA, CX3CR1, KISS1R | CASP6 2721/4885NSD2 2734/4885DUSP3 1245/4885 |
| US-20210236539-A1 | METHOD OF PROPHYLAXIS OF ZIKA VIRUS INFECTION | NAPA, CX3CR1, KISS1R | CASP6 2721/4885NSD2 2734/4885DUSP3 1245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.